Aurinia Pharmaceuticals Inc. (AUPH) Balance Sheet

NASDAQ: AUPHAssets, liabilities, debt and equity over 10 years.

AUPH balance sheet, 2025

December 31, 2025 · U.S. dollars

$751.6M assets = $170.3M liabilities + $581.3M equity

What it owns$751.6MCash & ST investments: $398.0M (53.0%)Cash & ST investments$398.0M · 53%Receivables: $41.5M (5.5%)Inventory: $45.7M (6.1%)Inventory $45.7MOther current: $6.8M (0.9%)PP&E: $79.6M (10.6%)PP&E $79.6MGoodwill & intangibles: $3.8M (0.5%)Other non-current: $176.3M (23.5%)Other non-current$176.3M · 23%=How it is financed$751.6MCurrent liabilities: $93.7M (12.5%)Current liabilities$93.7M · 12%Other LT liabilities: $76.5M (10.2%)$76.5MShareholders’ equity: $581.3M (77.3%)Shareholders’ equity$581.3M · 77%

Both columns are drawn to the same scale: what AUPH owns equals what it owes plus shareholders’ equity. Hover a block for its value.

AUPH financial health

Current ratio5.25
Comfortable · current assets cover current liabilities 5.25×
Debt / equity0.13
Low leverage · $0.13 of debt for each $1 of equity
Equity / assets77.3%
Equity-funded · of assets funded by shareholders
Cash / debt532.0%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.5%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

AUPH balance sheet trends, 2016–2025

Aurinia Pharmaceuticals Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$57.0M2016$751.6M2025+33.2%/yr
Total liabilities$21.0M2016$170.3M2025+26.1%/yr
Shareholders’ equity$36.0M2016$581.3M2025+36.2%/yr
Cash & short-term investments$39.6M2016$398.0M2025+29.2%/yr
Total debt$12.1M2016$74.8M2025+22.5%/yr
Net cash (debt)$27.6M2016$323.2M2025+$295.6M
Working capital$33.5M2016$398.2M2025+$364.8M
Book value per share$1.022016$4.192025+17.0%/yr
Current ratio5.2220165.252025+0.03
Debt / equity0.3420160.132025−0.21
Shares outstanding35.3M2016138.7M2025+16.4%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

AUPH assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

AUPH liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

AUPH debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

AUPH balance sheet

Aurinia Pharmaceuticals Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$398.0M$358.5M$350.5M$389.4M$466.1M$398.3M$306.0M$125.9M$173.5M$39.6M
Cash & equivalents$80.2M$83.4M$48.9M$94.2M$231.9M$272.4M$306.0M$118.0M$165.6M$39.6M
Short-term investments$317.8M$275.0M$301.6M$295.2M$234.2M$126.0M$0$7.9M$7.8M$0
Receivables$41.5M$36.5M$24.1M$13.5M$15.4M$51,000$368,000$217,000$109,000$86,000
Inventory$45.7M$39.2M$39.7M$24.8M$19.3M$13.9M$0$0−$109,000$1
Other current assets$6.8M$12.3M$10.5M$14.9M$12.5M$7.1M$8.8M$6.8M$1.8M$1.7M
Total current assets$492.0M$446.6M$424.8M$442.5M$513.3M$419.4M$315.1M$132.8M$175.3M$41.4M
Property, plant & equipment (net)$79.6M$98.9M$116.6M$8.6M$9.8M$10.3M$93,000$41,000$31,000$29,000
Goodwill & intangible assets$3.8M$4.4M$5.0M$6.4M$8.4M$9.3M$8.9M$12.6M$14.1M$15.6M
Long-term investments$0$0$201,000$0$0$24.4M$0$0$0$0
Other non-current assets$176.3M$823,000$1.5M$13.3M$11.8M$247,000$209,000$358,000$448,000$0
Total assets$751.6M$550.6M$548.1M$470.9M$543.4M$463.7M$324.3M$145.9M$189.8M$57.0M
Liabilities
Accounts payable$3.3M$5.2M$4.3M$3.1M$3.9M$2.6M$4.2M$7.1M$3.8M$2.9M
Short-term debt$17.6M$15.1M$15.6M$936,000$1.1M$788,000$6.9M$118,000$4.1M$2.9M
Deferred revenue$3.7M$11.0M$4.8M$3.1M$190,000$21.4M$118,000$118,000$118,000$118,000
Total current liabilities$93.7M$97.8M$77.2M$46.1M$40.6M$32.0M$11.3M$7.3M$8.2M$7.9M
Long-term debt$0$0$0$0$0$0$0$0$11.8M$9.1M
Lease obligations$74.8M$79.4M$97.6M$8.1M$8.7M$8.4M————
Other long-term liabilities$76.5M$75.4M$92.9M$19.3M$23.6M$23.9M$14.4M$26.0M$4.2M$4.0M
Total liabilities$170.3M$173.2M$170.1M$65.4M$64.3M$55.9M$25.7M$33.3M$24.1M$21.0M
Shareholders' equity
Common stock & paid-in capital$1.12B$1.19B$1.20B$1.19B$1.18B$944.3M$746.5M$504.6M$499.2M$299.8M
Retained earnings (deficit)−$649.4M−$936.6M−$942.3M−$864.3M−$756.1M−$575.2M−$472.5M−$416.0M−$351.8M−$281.0M
Accumulated other comprehensive income−$599,000−$647,000−$730,000−$1.1M−$852,000−$805,000−$805,000−$805,000−$883,000−$805,000
Total shareholders' equity$581.3M$377.5M$378.0M$405.4M$479.1M$407.8M$298.6M$112.6M$165.7M$36.0M
Key figures
Total debt$74.8M$79.4M$97.6M$8.1M$8.7M$8.4M$6.9M$118,000$15.9M$12.1M
Net cash (debt)$323.2M$279.1M$252.9M$381.3M$457.3M$389.9M$299.1M$125.7M$157.6M$27.6M
Working capital$398.2M$348.8M$347.6M$396.4M$472.7M$387.4M$303.8M$125.6M$167.1M$33.5M
Tangible book value$577.6M$373.1M$373.0M$399.0M$470.7M$398.4M$289.7M$100.0M$151.6M$20.4M
Book value per share$4.19$2.58$2.64$2.86$3.70$3.44$3.21$1.33$2.15$1.02
Shares outstanding138.7M146.2M143.2M141.9M129.4M118.5M93.0M84.8M76.9M35.3M
Current ratio5.254.575.509.6012.6313.1127.9018.3021.505.22
Quick ratio4.694.044.858.7411.8512.4527.1317.3621.305.01
Debt / equity0.130.210.260.020.020.020.020.000.100.34
Equity / assets77.3%68.6%69.0%86.1%88.2%87.9%92.1%77.2%87.3%63.1%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.

AUPH financial position

At the end of fiscal 2025 (December 31, 2025), Aurinia Pharmaceuticals had total assets of $751.6 million (up 36.5% from a year earlier), total liabilities of $170.3 million and shareholders' equity of $581.3 million. It held $398.0 million in cash and short-term investments against $74.8 million of debt, a net cash position of $323.2 million. Its current ratio was 5.25. In the latest quarter (ended June 30, 2026) total assets were $792.3 million and equity $614.9 million.

Related: AUPH income statement, AUPH cash flow statement, AUPH key metrics. See the AUPH stock overview for the latest quote and news.

AUPH balance sheet FAQ

What are Aurinia Pharmaceuticals's total assets?

Aurinia Pharmaceuticals reported total assets of $751.6 million at the end of fiscal 2025 (December 31, 2025), compared with $550.6 million a year earlier.

How much debt does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals had $74.8 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.13.

How much cash does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals held $398.0 million in cash and short-term investments at the end of fiscal 2025; with $74.8 million of debt that is net cash of $323.2 million.

What is Aurinia Pharmaceuticals's book value?

Aurinia Pharmaceuticals's shareholders' equity (book value) was $581.3 million at the end of fiscal 2025, or $4.19 per share.

What is Aurinia Pharmaceuticals's current ratio?

Aurinia Pharmaceuticals had current assets of $492.0 million and current liabilities of $93.7 million, a current ratio of 5.25 (it can cover its short-term obligations).

How much goodwill does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals carried $3.8 million of goodwill and intangible assets, 0.5% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet